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ABSTRACT 
 
Background: Catheter of atrial fibrillation is still challenging because of the high degree of 
variability of the pulmonary vein anatomy. Therefore, 3D imaging systems are frequently used prior 
to an ablation procedure. Three-dimensional transesophageal echocardiography provides an 
excellent overview over the individual left atrial morphology without some of the limitations 
associated with other imaging techniques.   
Methods: In 50 patients, three-dimensional transesophageal echocardiography was performed 
immediately prior to an ablation procedure. The images were available throughout the ablation 
procedure. In most of the patients with paroxysmal atrial fibrillation, the cryoablation technique was 
used (Arctic Front Balloon, CryoCath Technologies/Medtronic; group A2). In the other patients, a 
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circumferential pulmonary vein ablation was performed using the CARTO system (Biosense 
Webster; group A1 (paroxysmal atrial fibrillation), group B (persistent atrial fibrillation)).  
Results: A three-dimensional transesophageal echocardiography could be performed successfully 
in all patients and all four pulmonary vein ostia could be evaluated in 84% of patients. The image 
quality was excellent in the majority of patients and several variations of the pulmonary vein 
anatomy could be visualized precisely. The findings obtained by three-dimensional 
transesophageal echocardiography correlated well with the pulmonary vein angiographies 
performed during the ablation procedures. At 24-month follow-up, 76% of all patients were free 
from an arrhythmia recurrence (group A1: 81.8%, group A2: 78.9%, group B: 70.0%).  There were 
no major complications.   
Conclusions: AF ablation procedures can be performed safely and effectively based on prior 3D 
TEE imaging.   
 
 
Keywords: Catheter ablation; atrial fibrillation; pulmonary veins; transesophageal echocardiography. 
 
1. INTRODUCTION 
 
Catheter ablation has become the first line of 
therapy in patients with symptomatic, recurrent, 
drug-refractory atrial fibrillation (AF; [1-16]). 
However, it is still challenging because of the high 
degree of variability of the pulmonary vein (PV) 
anatomy. Therefore, 3D imaging systems (multi-
detector spiral computed tomography (MDCT) or 
magnetic resonance imaging (MRI)) are 
frequently used prior to an ablation procedure.  
 
These three-dimensional imaging systems 
provide detailed information about the left atrial 
and pulmonary vein morphology. Obviously, the 
precise knowledge of the left atrial anatomy 
facilitates the ablation procedures and enhances 
the safety of these interventions. However, these 
imaging techniques (MDCT/MRI) are associated 
with significant limitations (such as radiation 
exposure (MDCT), inappropriate image quality in 
the presence of atrial fibrillation with rapid 
ventricular response (especially MRI) and 
addtitional costs).  
 
Alternatively, three-dimensional transesophageal 
echocardiography (3D TEE) provides an excellent 
overview over the individual left atrial morphology 
without most of the limitations associated with 
other imaging techniques [17-25].  
 
Therefore, the aim of our study was to assess the 
usefulness of 3D transesophageal 
echocardiography for evaluating the pulmonary 
vein anatomy prior to catheter ablation of atrial 
fibrillation. This study summarizes our experience 
with two different strategies of AF ablation after 
prior pulmonary vein imaging using three-
dimensional transesophageal echocardiography.  
 
2. METHODS 
 
2.1 Patient Population  
 
Fifty patients were enrolled in this study. All of 
them underwent 3D transesophageal 
echocardiography immediately before the ablation 
procedure, so that a 3D TEE reconstruction of the 
left atrium and the pulmonary veins could be 
generated. The study cohort comprised all 
patients who underwent catheter ablation of AF at 
our institution after prior 3D TEE imaging within 
the period of time mentioned below (consecutive 
patients). Patients undergoing catheter ablation 
without prior 3D TEE imaging were not taken into 
consideration for this study. 
 
All patients were highly symptomatic and at least 
one failed attempt of an antiarrhythmic drug 
therapy was a prerequisite for being accepted for 
catheter ablation.  
 
Table 1 summarizes clinical characteristics of the 
patients enrolled in our study. For all patients, this 
was the first AF ablation procedure.  
 
The ablation procedures were performed at our 
University Hospital Center between October  
2007 and May 2011. 
 
Inclusion criteria were (1) documented episodes 
of recurrent atrial fibrillation (≥ 30 seconds), (2) 
severe symptoms despite antiarrhythmic drug 
therapy (including beta-blockers) or prior attemps 
of electrical cardioversion, (3) ability and 
willingness to give informed consent, and (4) age 
between 18 and 85 years. Patients were not 
accepted for catheter ablation if one of the 
following conditions was present: severe valvular 
heart disease or any other concomitant cardiac 
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Table 1. Clinical data 
                                
 Group A Group A1 Group A2  Group B  P 
Patients 
   Men : Women 
30 
18 : 12 
11 
5 : 6  
19 
13  : 6 
20 
17  : 3  
0.07 
 
Age  
   Mean (SD) 
60.0 years 
(9.7 years) 
61.6 years  
(8.0 years) 
59.1 years  
(10.7 years) 
62.1 years  
(8.4 years) 
0.57 
 
Cardiac disease 
   None 
   CAD 
   DCM  
   Valvular heart 
   disease * 
   Arterial hypertension 
   Other 
 
13 
3 
0 
5 
 
9 
0 
 
8 
1 
0  
1 
 
1 
0  
 
5 
2 
0 
4 
 
8 
0 
 
2 
9 
1 
5 
 
2 
1 
0.05  
 
Previous cardiac surgery 1 0 1 0 0.43  
Left ventricular ejection  
fraction 
   Mean (SD) 
58.0 % 
(5.8 %) 
59.1 % 
(7.4 %) 
57.4 % 
(4.8 %) 
52.6 % 
(9.9 %) 
0.06  
 
Antiarrhythmic drug therapy 
prior to the  ablation 
procedure  
- Class Ic (e.g. Flecainide, 
  Propafenone) 
- Class III (e.g.   
  Amiodarone, Sotalol)  
- Beta-Blocker in   
  combination with a class  
  Ic or class III  
  antiarrhythmic drug  
- Beta-Blocker 
- Digitalis 
- Other  
 
 
 
1 
 
5 
 
16 / 7 
 
 
 
1 
0 
0 
 
 
 
0 
 
0 
 
7 / 3 
 
 
 
1 
0 
0 
 
 
 
1 
 
5 
 
9 / 4  
 
 
 
0 
0 
0 
 
 
 
2 
 
2 
 
3 / 7 
 
 
 
6 
0 
0 
0.68 
 
CAD  = Coronary artery disease; DCM = Dilated cardiomyopathy (left ventricular ejection fraction < 40 %); 
* not requiring surgery 
 
disease requiring surgery, severely impaired left 
ventricular function (left ventricular ejection 
fraction < 20%), left atrial diameter > 65 mm 
(parasternal long-axis view), left atrial thrombus, 
hyperthyroidism, severe renal insufficiency 
(creatinine ≥ 3 mg/dl) or another severe 
concomitant illness.  
 
2.2 Cardiac Imaging 
 
In all patients, a three-dimensional transeso-
phageal echocardiography was performed 
immediately before the ablation procedure (X7-2t, 
7 MHz; IE 33; Philips Healthcare, Best, The 
Netherlands). Real-time 3D images of the left 
atrium were obtained. The images were available 
throughout the ablation procedures. They were 
displayed in a synchronised way with the 
geometry created with the 3D mapping system (if 
available).  
The echocardiographic examination was 
performed extensively to acquire all relevant 
information about the left / right atrium, all cardiac 
valves, the left / right ventricular function and the 
aorta. In addition, 3D reconstructions of the left 
atrium and the pulmonary vein ostia were 
generated.  We aimed at visualizing all pulmonary 
vein ostia precisely in multiplanar views (including 
3D color Doppler datasets) and to reveal  all 
variations of the pulmonary vein anatomy 
(common ostia, accessory pulmonary veins) or 
the left atrium (very prominent left atrial 
appendage, extremely short distance between the 
left atrial appendage and the left superior 
pulmonary vein). The image quality was classified 
as (1) good, (2) acceptable or (3) not appropriate 
(for each pulmonay vein ostium). The grading 
“good” was used when PV ostia could be 
visualized precisely. The term “acceptable” was 
applied if the image quality was impaired (but still 
sufficient for analysing the PV anatomy). It was 
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documented which PVs could not be visualized. 
The variations of the PV anatomy were classified 
as given in Table 2. The TEE findings were 
compared with the results of the selective biplane 
pulmonary vein angiographies performed during 
the ablation procedure (see Tables 2 and 3). The 
data was analysed by three experienced 
cardiologists, who were familiar with three-
dimensional transesophageal echocardiography 
and pulmonary vein imaging (laboratory 
accredited by the European Association of 
Echocardiography).  
 
No other imaging techniques (MDCT or MRI) 
were used before or after the ablation procedures 
routinely.  
 
2.3 Ablation Procedure  
 
The ablation strategy was depending on the type 
of atrial fibrillation. 
 
In patients with paroxysmal atrial fibrillation, two 
strategies were used. In some patients with 
paroxysmal atrial fibrillation, a cicumferential 
pulmonary vein ablation was performed in 
combination with a potential-guided segmental 
approach in order to achieve complete pulmonary 
vein isolation (group A1; CARTO system  
(Biosense Webster, Diamond Bar, CA, USA)). In 
most of the patients with paroxysmal AF, the 
cryoballoon technique (Medtronic, Minneapolis, 
MN, USA) was used (group A2).  In patients with 
persistent atrial fibrillation, a circumferential 
pulmonary vein ablation was performed in 
combination with a potential-guided segmental 
approach to achieve complete pulmonary vein 
isolation ([20]; group B). Furthermore, a linear 
lesion was created at the roof of the left atrium in 
some patients. In addition, catheter ablation of the 
mitral isthmus was performed in selected cases 
(CARTO system ((Biosense Webster)).   
   
AF ablation procedures were performed under 
conscious sedation at our institution. For the 
electrophysiological study, vascular access was 
obtained via both femoral veins and the left 
femoral artery. A 2500-U IV bolus of heparin was 
given shortly thereafter. First, a 6-F decapolar 
catheter (Bard, Electrophysiology Division, 
Lowell, MA, USA) was positioned within the 
coronary sinus (CS). Then, a single (or double) 
transseptal puncture was performed under 
fluoroscopic guidance. Immediately before the 
transseptal puncture, a 5-F catheter was placed 
in the ascending aorta to mark this area and to 
enhance the safety of the procedure. In some 
patients no transseptal puncture was necessary 
because of a patent foramen ovale or a defect of 
the atrial septum.  
 
In group A1 and in group B, an irrigated-tip 
CARTO ablation catheter (NAVI-STAR; 7F, D-
type; 3.5-mm-tip; Biosense Webster) was 
positioned within the left atrium thereafter. 
Furthermore, a Lasso-catheter 2515; 7F; 
Biosense Webster) was placed in the left atrium. 
 
Then, a second iv bolus of heparin was 
administered. During the procedure, the activated 
clotting time (ACT) was determined at regular 
intervals to ensure an adequate anticoagulation 
(ACT between 250 and 300 s). Then, a selective 
biplane pulmonary vein angiography was 
performed (LAO (45°) projection and RAO (30°) 
view). After that, a geometry of the left atrium was 
created using the CARTO system and compared 
to the 3D TEE reconstructions. This allowed to 
correct potential shortcomings of the geometry 
created with the mapping system. The 3D                 
TEE reconstructions were displayed in a 
synchronized way throughout the ablation 
procedure.  
 
In the majority of patients, a standard stomach 
tube (Flocare Nutrisoft M, Nurtica Healthcare, 
Châtel-St.Denis, Switzerland) had been 
introduced via a nasogastric route immediately 
before the ablation procedure in order to mark the 
esophagus. Radiofrequency (RF) energy 
applications were avoided if there was a close 
anatomical relationship to the esophagus (or the 
power output was reduced as described 
previously [19]). 
 
First, a circumferential pulmonary vein ablation 
was performed in all patients in group A1 and in 
group B targeting the both left-sided pulmonary 
veins (43°C; 30 W (posterior wall) - 40 W (anterior 
wall)). In addition, a Lasso catheter was placed in 
the left superior or left inferior pulmonary vein. 
After completing the circumferential ablation line 
around the left-sided pulmonary veins, the left 
superior pulmonary vein and the left inferior 
pulmonary vein were reevaluated using the 
circular mapping catheter. If there was no 
complete PV isolation additional RF energy 
applications (43°C; (25-) 30 W) were applied 
using a segmental approach (during sinus rhythm 
/ CS pacing or ongoing AF). If the isolation of the
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Table 2. Left atrial anatomy (assessed by 3D TEE*  and/or  by invasive PV angiography**) 
 
 3D TEE  Invasive pulmonary vein 
angiography 
Common PV ostium  
    (Left PVs / right PVs)  
2 
(1  /  1) 
2 
(1  /  1) 
Accessory PVs   
    (Left PVs / right PVs)  
1 
(0  /  1) 
1 
(0  /  1) 
Early PV branching  
    LSPV 
    LIPV 
    RSPV 
    RIPV    
0 3 
0 
0 
2 
1 
Extremely short      
    distance between the 
    LAA and the LSPV  
3 n.d. 
Very prominent left  
    atrial appendage  
2 n.d. 
LAA = Left atrial appendage; LIPV = Left inferior pulmonary vein; LSPV = Left superior pulmonary vein;  
PV(s) = Pulmonary vein(s); RIPV = Right inferior pulmonary vein; RSPV: Right superior pulmonary vein;  
3D TEE = Three-dimensional transesophageal echocardiography, n.d. = Not determined 
 
Table 3. Mean diameter of the left-sided and right-sided pulmonary veins (as assessed by 
three-dimensional transesophageal echocardiography and by invasive pulmonary vein 
angiography) 
 
 LSPV LIPV RSPV RIPV 
Diameter of the main  
trunk* 
   Mean (SD)   
13.9 mm 
(3.9 mm) 
13.4 mm 
(3.9 mm) 
14.0 mm 
(2.8 mm) 
13.1 mm 
(3.2 mm) 
Diameter of the main 
trunk**    
   Mean (SD) 
17.3 mm 
(3.1 mm) 
 
16.8 mm 
(2.9 mm) 
 
16.1 mm 
(2.4 mm) 
 
14.9 mm 
(2.2 mm) 
 
P  0.41 0.27 0.17 0.43 
* as assessed by three-dimensional transesophageal echocardiography 
** as assessed by invasive pulmonary vein angiography (biplane) 
LIPV = Left inferior pulmonary vein; LSPV = Left superior pulmonary vein; 
RIPV = Right inferior pulmonary vein; RSPV: Right superior pulmonary vein 
 
left-sided PVs was assumed to be complete, the 
right-sided PVs were targeted in the same way.  
 
If atrial fibrillation was still present after 
completing the circumferential ablation lines and 
no residual PV potentials could be identified, an 
electrical cardioversion was performed. Then, all 
four pulmonary veins were reevaluated using the 
circumferential mapping catheter.  
 
Futhermore, a linear lesion at the LA roof was 
created in some patients in group B (43°C; 30-35 
W). In a few patients in group B, an additional 
mitral isthmus ablation was performed (especially 
if there was evidence for left atrial isthmus-
dependent flutter (43°C; 35-40 W)). Finally, the 
linear lesions at the LA roof were reevaluated 
during sinus rhythm. The ablation catheter was 
navigated back along the entire lesion to assess 
the presence of low-amplitude electrograms and 
the presence of double potentials or fractionated 
electrograms. If sharp high-amplitude 
electrograms were noted, additional RF 
applications were delivered at these sites in order 
to achieve a complete ablation line. In addition, 
the linear lesions to the mitral annulus were 
reevaluated (anterior mitral isthmus line).  
 
At the end of the ablation procedure, the 
completeness of the pulmonary vein isolation and 
of all linear lesions was reassessed after a 
waiting period of at least 20 minutes. Repeat 
selective pulmonary vein angiographies were 
performed of all PVs. In addition, catheter 
ablation of the right atrial isthmus was performed 
in patients with inducible or clinically documented 
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episodes of typical atrial flutter. The 
completeness of the right atrial isthmus lines was 
confirmed by differential pacing maneuvers in all 
cases.  
 
For the ablation procedure, a Bard EP system 
(LabSystem Pro, EP Recording System; Bard, 
Electrophysiology Division, Lowell, MA, USA) and 
a Stockert RF generator (EP-shuttle; Stockert, 
Freiburg, Germany) were used. High-resolution 
X-ray imaging was provided by a Philips device 
(Philips Medical Systems, Best,  The 
Netherlands).   
 
Some modifications were made in group A2. In 
these patients, the cryoballoon technique was 
used. After performing the pulmonary vein 
angiographies, the decision was made to use a 
23 mm or 28 mm cryoballoon (Arctic Front; 
Medtronic, Minneapolis, MN, USA). The choice of 
the balloon diameter was determined by the left 
atrial anatomy observed on the pre-procedural 3D 
TEE examinations as well as by the 
intraprocedural PV angiographies. Once the 
FlexCath Sheath (Medtronic) had been 
introduced into the left atrium via a transseptal 
puncture, the Arctic Front cryocatheter was 
passed through the FlexCath lumen over the 
guide wire and guided into the left atrium in a 
deflated state. Then, the guide wire was placed in 
the left superior pulmonary vein (LSPV). After 
that, the cryoballoon was inflated in the atrium 
and positioned at the ostium of the LSPV. Balloon 
position was verified by injection of contrast. 
Every effort was made to obtain a complete 
occlusion with contrast remaining in the vein. 
Then, a minimum of two cryoapplications was 
performed (lasting 5 minutes each). After that, 
successful pulmonary vein isolation was verified 
using a circular mapping catheter (Lasso 2515; 
Biosense Webster). In some patients, we used 
the Achieve inner lumen circular mapping 
catheter (loop diameter: 15 or 20 mm; Medtronic) 
instead of a Lasso catheter and a standard guide 
wire. If there was no complete PV isolation 
additional cryoapplications were performed 
(maximum duration: 5 minutes/cryoapplication).  
After having completed the isolation of the LSPV, 
the LIPV was targeted in the same way. Then, 
cryoablation of the right superior and right inferior 
pulmonary vein was performed. During 
cryoablation of the antrum of the right-sided 
pulmonary veins, diaphragm movement was 
monitored by either continuous phrenic nerve 
stimulation with a right atrial stimulation catheter 
positioned superiorly compared with the balloon 
position or by continuous monitoring of the 
phrenic movement during spontaneous breathing 
[26]. Finally, the completeness of the isolation of 
all four pulmonary veins was reassessed after a 
waiting period of at least 20 minutes. Additional 
cryoapplications were delivered if necessary. In 
no complete PV isolation could be achieved with 
a maximum of 5 cryoapplications using the 
cryoballoon device chosen at the beginning of the 
procedure a cryoballoon with a different diameter 
or a standard cryoablation catheter (Frezzor Max; 
Medtronic; targeted temperature: - 75°C; 
maximum duration of a single cryoapplication: 4 
minutes) was used for further cryoapplications.  
 
During the cryoablation procedure activated 
clotting time was maintained between 250 and 
350 seconds. In some patients in group A2, three-
dimensional transesophageal echocardiography 
was used to guide the transseptal puncture and 
the positioning of the cryoballoon.  
 
2.4 Follow-up  
 
After hospital discharge, patients were seen 
regularly on an outpatient basis. One month after 
the procedure, a physical examination, a resting 
electrocardiogram (ECG) and a transthoracic 
echocardiogram were performed. The patients 
were questioned whether there was any evidence 
for an arrhythmia recurrence. In addition, a long-
term ECG recording (24-h) was performed.  
 
Three months after the ablation procedure, the 
patients were re-examined in the same way 
except for the fact that a 7-day Holter monitoring 
was performed and that each patient underwent a 
repeat three-dimensional transesophageal 
echocardiography to rule out a pulmonary vein 
stenosis. Then, the patients were seen at 3-
month intervals if asymptomatic. If there was an 
arrhythmia recurrence or other problems 
occurred, the further follow-up and future strategy 
(e.g. medical therapy, electrical cardioversion, 
repeat ablation procedure) were planned on an 
individual basis.  
 
Twelve months and twenty-four months after the 
ablation procedure another 7-day Holter 
monitoring was performed. A blanking period of 3 
months was employed after ablation when 
evaluating the follow-up results. 
 
In addition, all patients were given a 
questionnaire 24 months after the ablation 
procedure. The aim of this questionnaire was to 
evaluate the clinical status of the patients and to 
reveal whether there was any evidence for 
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arrhythmia recurrences not detected by the long-
term ECG recordings [20].  
 
Oral anticoagulation was continued for at least 3 
months after the procedure in all patients and was 
discontinued only in patients with a CHADS2 
score ≤ 1 thereafter. Since October 2010 the 
CHADS2-VASc score was used for risk 
assessment and oral anticoagulation was only 
discontinued in patients with a CHADS2-VASc 
score   ≤ 1 three months after the ablation 
procedure (vitamin K antagonist / novel oral 
anticoagulants). During the first three months 
after catheter ablation the patients received the 
same antiarrhythmic medication as prior to the 
ablation procedure. If there was no evidence for 
an arrhythmia recurrence all antiarrhythmic drugs 
were discontinued thereafter except for beta-
blockers.  
 
2.5 Statistical Analysis   
 
Clinical characteristics of the three study groups 
were compared at baseline to discover potential 
sources of bias. All parameters with a normal 
distribution are given as mean (± 1 standard 
deviation (SD)). Age, left ventricular ejection 
fraction, total procedure time, fluoroscopy dosage 
and follow-up duration were compared using an 
one-way ANOVA. All other parameters 
(underlying cardiac disease, gender) were 
analysed using the chi-square test.  
 
The chi-square test was also used for analysing 
the clinical endpoints (arrhythmia recurrence rate 
at 12/24-month follow-up). The diameters of all 
pulmonary veins assessed by 3D TEE and 
invasive angiography were compared using t-
tests. 
 
Significance was accepted if the P value was ≤ 
0.05.  
 
The statistical package of JMP (Version 3.2.6, 
SAS Institute, Cary, NC, USA) was used for data 
analysis.  
 
3. RESULTS 
 
Fifty patients were enrolled in this study between 
October 2007 and May 2011. All of them suffered 
from recurrent paroxysmal or persistent atrial 
fibrillation. In all patients, catheter ablation was 
performed after prior 3D TEE data acquisition. 
Catheter ablation was performed for paroxysmal 
atrial fibrillation in 30 patients and for persistent 
atrial fibrillation in 20 patients. In all patients, this 
was the first ablation procedure. The ablation 
procedure could be performed as planned in all 
patients. 
 
3.1 Ablation Strategy 
 
In some patients with paroxysmal atrial fibrillation 
an anatomically-based circumferential pulmonary 
vein ablation in combination with a potential-
guided segmental approach was performed 
(group A1: 11 patients; Carto system (Biosense 
Webster)).  
 
In the remaining 19 patients with paroxysmal 
atrial fibrillation, the cryoballoon technique was 
used (group A2; Medtronic). In all of them, a 28 
mm cryoballoon was chosen at the beginning of 
the procedure. In 4 patients, a second 
cryoballoon (23 mm; n = 1)  or a standard 
cryoablation catheter (Freezor Max, Medtronic; n 
= 3) had to be used to achieve complete 
pulmonary vein isolation. 
 
In all patients with persistent atrial fibrillation (n = 
20), an anatomically-based circumferential 
pulmonary vein ablation in combination with a 
potential-guided segmental strategy was 
performed as the standard approach (group B). 
Furthermore, a linear lesion was created at the 
roof of the left atrium in 7 patients with persistent 
AF. In 2 patients in group B, additional catheter 
ablation of the mitral isthmus was performed.  
 
In addition, catheter ablation of the right atrial 
isthmus was performed in 5 patients in group A 
(A1: 4 patients, A2: 1 patient) and in 2 patients in 
group B.  
 
3.2 Procedural Results 
 
The ablation procedure could be performed as 
planned in all patients. The mean procedure time 
was 171 minutes (SD ± 49 minutes) in group A 
(A1: 199 minutes (SD ± 36 minutes) / A2: 158 
minutes (SD ± 48 minutes)) and 163 minutes (SD 
± 51 minutes) in group B (P = 0.1). This included 
all preparations and a waiting period (20 minutes) 
at the end of the procedure for a final reevaluation 
of the completeness of the pulmonary vein 
isolation/linear lesions. The mean fluoroscopy 
dosage was 2918 cGycm² (SD ± 1676 cGycm²) in 
group A (A1: 2639 cGycm² (SD ± 1516 cGycm²) / 
A2: 3079 cGycm² (SD ± 1769 cGycm²)) and 3013 
cGycm² (SD ± 1169 cGycm²) in group B (P = 0.3). 
 
In group A1, an anatomically-based 
circumferential pulmonary vein ablation in 
  
 
 
Kettering et al.; CA, 6(2): 1-18, 2017; Article no.CA.34273 
 
 
 
8 
 
combination with a potential-guided segmental 
approach was performed successfully in all 
patients. In this group, all four pulmonary veins 
could be isolated successfully in all patients 
(documented using a circular mapping catheter). 
The circumferential strategy had to be combined 
with potential-guided segmental RF-applications 
in the majority of patients (7/11).  
 
In group A2, all cryoablation procedures could be 
completed successfully using this technique. A 
mean number of 3.9 PVs (SD ± 0.7 PVs) were 
isolated per patient.  
  
In group B, the circumferential ablation lines 
around the left-sided and right-sided pulmonary 
veins could be performed successfully in all 
patients according to anatomical criteria. 
However, this did not result in complete 
pulmonary vein isolation in most cases (when 
using the aforementioned moderate ablation 
parameter settings as well as a sufficient safety 
margin to the pulmonary vein ostia and the 
esophagus). Therefore, this circumferential 
strategy had to be combined with a potential-
guided segmental approach to achieve complete 
pulmonary vein isolation in the majority of  
patients in group B (12 of 20 patients). Finally, a 
mean number of 3.8 pulmonary veins                 
(SD ± 0.9 PVs) were isolated per patient in      
group B.  
 
 
 
(A) 
 
 
 
(B) 
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(C) 
 
 
 
(D) 
 
Fig. 1. Three-dimensional TEE-reconstruction of the left atrium providing an overview over the 
left-sided pulmonary veins and the left atrial appendage (a, b). Evaluation of the flow within 
the ostium of the LSPV (c) and the LIPV (d; 3D color Doppler datasets). 
The left pulmonary veins have separate ostia (rather close together) and there is no 
pulmonary vein stenosis 
LAA = Left atrial appendage, LIPV = Left inferior pulmonary vein, LSPV = Left superior pulmonary vein,  
MV = Mitral valve, TEE = Transesophageal echocardiography 
 
A linear lesion at the LA roof could be created 
successfully in seven patients in this group (7/7 
patients). In addition, a continuous linear lesion 
was created at the mitral isthmus in 2 patients 
(10%) in group B. A mitral isthmus ablation was 
only performed in patients with spontaneously 
occuring or inducible left atrial isthmus-dependent  
flutter.  
Successful catheter ablation of the right atrial 
isthmus was performed in a total of 7 patients 
(group A1: 4 patients, group A2: 1 patient, group 
B: 2 patients). Catheter ablation of the 
cavotricuspid isthmus was only performed in 
patients with spontaneously occuring or inducible 
typical atrial flutter. 
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Fig. 2. Three-dimensional TEE-reconstruction (a) and 3D MDCT-reconstruction (b) providing 
an overview over the left atrial anatomy. Note the large left atrial appendage (LAA) and its 
close anatomical relationship to the left superior pulmonary vein (LSPV) 
CT = Computed tomography 
 
 
 
(A) 
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 (B) 
 
Fig. 3. Three-dimensional TEE-reconstruction (a) and 3D color Doppler dataset (b)  
revealing a common ostium of the right pulmonary veins (RPVs) 
 
There were no major complications (e.g. cardiac 
tamponade, transient ischemic attacks (TIAs) or 
stroke, significant pulmonary vein stenosis (≥ 
70%), periprocedural death) during the procedure 
in both groups.  
 
3.3 Clinical Outcome    
    
The mean follow-up was 795 days (SD ± 423 
days) in group A  and 966 days (SD ± 208 days) 
in group B (P = 0.1). The mean overall follow-up 
was 864 days (SD ± 360 days). All patients were 
enrolled in the clinical outcome analysis even if 
the PVs could not be visualized appropriately by 
3D TEE. 
 
Twelve months after the ablation procedure, 
86.7% of the patients in group A (26 / 30; A1: 
90.6% (10 / 11) / A2: 84.2% (16 / 19)) and 75.0% 
of the patients in group B (15 / 20) were free from 
an arrhythmia recurrence (P = 0.82; in total: 41 / 
50 patients (82.0%)). Two years after the 
procedure, the overall success rate was  76% (no 
arrhythmia recurrence in 38 out of 50 patients). 
Twenty-four out of 30 patients in group A (80.0%; 
A1: 81.8% (9 / 11 patients) / A2: 78.9 % (15 / 19 
patients)) and 14 out of 20 patients in group B 
(70.0%) were still free from an arrhythmia 
recurrence (P = 0.75).  
 
According to the analysis of the questionnaire,        
39 / 50 patients (78%) were completely 
asymptomatic at 24-month follow-up.  
 
There were no major complications during or after 
the ablation procedures (including a follow-up 
duration of 24 months). Minor complications were 
observed in 9 patients (group: A1 / A2 / B: 2 / 1 / 
5 patients; groin hematoma: 3 patients, 
pulmonary vein stenosis 30-70%: 0 patients, 
noninfectious pericarditis: 3 patients, minor 
pericardial effusion: 1 patient, hyperthyroidism: 1 
patient, residual defect of the atrial septum: 1 
patient).     
 
Analysing the clinical course of the patients who 
experienced an arrhythmia recurrence during 
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follow-up, 7-day Holter monitoring revealed 
paroxysmal atrial fibrillation in 9 patients (group A: 
7 patients (A1: 6 / A2: 1); group B: 2 patients) and 
persistent atrial fibrillation in 3 patients (group A: 
2 patients (A1: 1 / A2: 1 ); group B: 1 patients). 
No modification of the antiarrhythmic medication 
and no repeat ablation procedure was required in 
3 patients (group A1/A2/B: 1/0/2 patients) with an 
arrhythmia recurrence because they were almost 
asymptomatic. In 3 patients (group A1/A2/B: 
1/0/2) with a symptomatic arrhythmia recurrence 
symptoms could be controlled by modifying the 
antiarrhythmic drug therapy or an electrical 
cardioversion. Six patients with symptomatic 
arrhythmia recurrences had to undergo another 
ablation procedure (group A1/A2/B:  0 / 4 / 2 
patients).  
 
Three months after the ablation procedure, all 
antiarrhythmic drugs (except for beta-blockers) 
were discontinued in all but 5 patients. Two 
patients remained on a class III antiarrhythmic 
drug (amiodarone: group A1/A2/B: 1/0/1) and 
three patients continued to take a class Ic 
antiarrhythmic drug (flecainide: 1/1/1). 
 
3.4 Cardiac Imaging    
 
A 3D TEE could be performed successfully in all 
patients immediately prior to the ablation 
procedure (only in 2 patients the TEE probe was 
left in place during the entire ablation procedure 
for real time monitoring of the intervention). All PV 
ostia could be evaluated in 42 / 50 patients (84%; 
group A1/A2/B: 8/16/18 patients). In 8 patients 
(group A1/A2/B: 3/3/2), the right PVs could not be 
evaluated (RSPV: 0 patients; RIPV: 2 patients; 
RSPV+RIPV: 6 patients). The left-sided PVs 
could not be evaluated in 5/50 patients (group 
A1/A2/B: 3/0/2 patients). In all of these patients, 
both left-sided PVs (and the right-sided PVs) 
could not be evaluated.  The image quality was 
good in 42/50 patients (84%; i.e. all PV ostia 
could be visualized precisely). In 5 / 50 patients, 
the image quality was moderate (10%). Only poor 
image quality could be obtained in 3/50 patients 
(6%). The grading "poor image quality" was used 
when the PVs could hardly be visualized.                
Poor image quality was mostly due to the                    
fact that the right-sided PVs were difficult to 
visualize.  
 
Poor or insufficient image quality was mostly due 
to anatomical reasons. The underlying rhythm did 
not influence the image quality very much and the 
image quality was acceptable even if AF with 
rapid ventricular response was present during the 
examination in most cases. 
 
In all patients, a 3D TEE-reconstruction of the left 
atrium could be generated. These 3D 
reconstructions were displayed in a synchronised 
way during the ablation procedure. The 3D TEE - 
models provided an excellent overview over the 
anatomy of the left atrium in all cases. They 
revealed a high degree of variability with regard to 
the individual anatomy. There was a large left 
atrial appendage in 2 patients (group A: 1, group 
B: 1). The distance between the left atrial 
appendage and the left superior pulmonary vein 
was extremely short (< 5 mm (measured on the 
3D-TEE models)) in 3 patients resulting in a 
difficult ablation procedure (group A1/A2/B:  1 / 1 / 
1 patients).  
                         
The 3D reconstructions did also provide valuable 
information about the anatomy of the pulmonary 
veins (see Table 2). They provided a good 
overview over the anatomy of the pulmonary 
veins similar to standard CT or MRI scans. In 2 
patients, there was a common ostium of the left-
sided (n = 1) or right-sided pulmonary veins (n = 
1).  There was an accessory pulmonary vein in 1 
patient (right: 1, left: 0). The TEE findings 
concerning the anatomy of the pulmonary veins 
were confirmed by invasive pulmonary vein 
angiography (biplane) in all cases. In addition, 
invasive pulmonary vein angiography revealed a 
branching of a pulmonary vein close to the orifice 
/ LA-PV junction (within ≤ 0.5 cm from the ostium) 
in 3 patients (LSPV: 0, LIPV: 0, RSPV: 2, RIPV: 
1), which could not be visualized by 3D TEE.   
The mean diameter of the main trunk of all 
pulmonary veins is given in Table 3 (as assessed 
by three-dimensional transesophageal 
echocardiography and invasive pulmonary vein 
angiography). There were no significant 
differences between the two techniques with 
regard to the estimated PV diameter (although 
the PV diameters determined by 3D TEE tended 
to be slightly smaller than those determined by 
invasive pulmonary vein angiography). In 
addition, the 3D TEE-reconstructions provided 
valuable information for planning linear lesions by 
providing an excellent overview over the 
individual left atrial and PV morphology.  
 
In summary, these 3D TEE-reconstructions 
provide detailed knowledge of the individual left 
atrial and PV morphology thereby facilitating the 
ablation procedure. The ablation procedures were 
strongly influenced by the use of the 3D
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reconstructions. In group A, the information 
derived from the 3D TEE-reconstructions was 
valuable to decide whether the patients were 
scheduled for radiofrequency catheter ablation or 
for a cryoablation procedure. In 1 patient in group 
A, we refrained from using the cryoballoon 
technique because of an unfavourable PV 
anatomy (common PV ostium). 
   
The knowledge of the individual left atrial and PV 
morphology had direct implications for the 
ablation strategy. Thereby, typical pitfalls were 
revealed which are associated with a high risk of 
serious complications such as pulmonary vein 
stenosis. In 2 patients (group A: 1 patient, group 
B: 1 patient) we refrained from isolating one (1 
patient) or two (1 patient) pulmonary veins 
because of an unfavourable pulmonary vein 
morphology (e.g. small diameter, endangered 
side branches or a pre-existing moderate stenosis 
(n = 1)).   
   
Additionally, an incomplete PV isolation was 
accepted in 3 patients (group A: 1 patient, group 
B: 2 patients; one PV: 3 patients, two PVs: 0 
patients). An incomplete PV isolation was 
accepted in 2 patients in group B because of a 
small distance between the LAA and side 
branches of the left superior pulmonary vein. In 
one patient in group A2, an incomplete isolation 
of a small right inferior pulmonary vein was 
accepted. This PV could not be isolated 
completely with the first gerneration cryoballoon 
because of an atypical drainage pattern (very 
inferior) and an unfavourable relationship to the 
transseptal access.  Furthermore, an incomplete 
isolation of an accessory PV was accepted in 1 
patient. 
 
In patients undergoing a cryoballoon procedure, 
the 3-D TEE reconstructions were very helpful for 
chosing the initial balloon diameter. Furthermore, 
they were helpful to decide whether to use a 
cryoballoon with a different diameter or a 
standard cryoablation catheter in case of 
incomplete PV isolation after several 
cryoapplicatons with the type of cryoballoon 
chosen at the beginning of the procedure.  
 
In addition, three-dimensional transesophageal 
echocardiography was used for visualization of 
the cryoballoon and the circular mapping catheter 
during the ablation procedure in 2 patients (see 
Fig. 4). Thereby, an excellent overview could be 
obtained concerning the position of the catheters 
and their anatomical relationship to the relevant 
left atrial structures.   
 
4. DISCUSSION  
 
Catheter ablation has become an important 
therapeutic option for patients with highly 
symptomatic and drug-refractory atrial fibrillation. 
Nevertheless, catheter ablation of atrial fibrillation 
is still a challenge. This is partially due to the high 
degree of variability with regard to the individual 
anatomy. Therefore, 3D imaging systems (MRI 
and MDCT) are frequently used prior to an 
ablation procedure. They provide detailed 
information about the individual left atrial 
anatomy, thereby facilitating the ablation 
procedure. However, these imaging techniques 
are associated with significant limitations (e.g. 
radiation exposure (MDCT), inappropriate image 
quality in the presence of atrial fibrillation with 
rapid atrioventricular nodal conduction (especially 
MRI), additional costs).  
 
Therefore, we have evaluated the usefulness of 
three-dimensional transesophageal echocardio-
graphy for assessing the left atrial anatomy prior 
to catheter ablation of atrial fibrillation (either by 
radiofrequency catheter ablation or by 
cryoablation). There is only few data about the 
usefulness of 3D transesophageal 
echocardiography in the electrophysiology 
laboratory [25,27] and no sufficient data 
concerning 3D TEE for preprocedural imaging 
prior to catheter abklation of AF.  
 
4.1 Main Results 
 
Catheter ablation of paroxysmal atrial fibrillation 
could be performed successfully in 11 patients in 
group A using radiofrequency catheter ablation 
(group A1) and in 19 patients using cryoablation 
(group A2) based on prior 3D TEE imaging. In 
group B, catheter ablation of persistent atrial 
fibrillation could be performed successfully in 
20/20 patients using radiofrequency catheter 
ablation and a basically circumferential ablation 
strategy.   
 
Two years after the ablation procedure, 80.0% of 
all patients in group A (24 / 30) were still free from 
an arrhythmia recurrence compared to 70% of 
patients in group B (14 / 20; P = 0.75).                       
The   overall success rate was 76% at 24-month 
follow-up. There were no major complications 
during or after the ablation procedures in both 
groups.  
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Fig. 4. Cryoablation of atrial fibrillation: Visualization of the cryoballoon (Arctic Front; 
Medtronic) and the circular mapping catheter (Lasso 2515; Biosense Webster) during the 
ablation procedure by three-dimensional transesophageal echocardiography 
LA = Left atrium 
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Three-dimensional transesophageal echocardio-
graphy could be performed successfully in all 
patients prior to the ablation procedure. All 
pulmonary vein ostia could be evaluated in 42/50 
patients (84%). The image quality was good in 
the majority of cases and several variations of the 
left atrial anatomy could be visualized precisely. 
The image quality was acceptable even if AF with 
rapid ventricular response was present during the 
examination and the TEE findings correlated well 
with the PV angiographies performed during the 
ablation procedure.    
                                                                   
However, invasive pulmonary vein angiography 
was superior to 3D TEE with regard to the 
detection of side branches close to the pulmonary 
vein ostium.  Although the pulmonary vein 
diameter determined by 3D TEE tended to be 
slightly smaller than the values obtained by 
invasive pulmonary vein angiography this was not 
statistically significant. However, a future study 
with a larger patient cohort is needed to rule out a 
possible underestimation of the PV diameter  by 
3D TEE.  
 
The results of our study demonstrate that catheter 
ablation of atrial fibrillation can be performed 
safely and effectively using radiofrequency 
catheter ablation or cryoablation after pre-
procedural 3D TEE imaging. Three-dimensional 
transesophageal echocardiography overcomes 
most of the limitations of other imaging 
techniques (CT/MRI) frequently used for 
evaluation of the PV anatomy (such as radiation 
exposure and inappropriate image quality in the 
presence of atrial fibrillation with rapid 
atrioventricular nodal conduction). A TEE should 
be performed prior to an AF ablation procedure to 
rule out the presence of a left atrial thrombus in 
all patients anyway. Thus, a 3D TEE does not 
result in additional patient discomfort or cost and 
is less time-consuming than other techniques 
(average time needed for 3D TEE data 
acquisition: 2-3 minutes). This suggests that 3D 
TEE might be the preferred imaging technique for 
analysing the left atrial anatomy prior to an 
ablation procedure in the future. By using 3D TEE 
the radiation exposure for preprocedural imaging 
can be reduced to zero and the costs can be 
reduced significantly depending on the technical 
resources of the institution as well as the national 
healthcare system.  
 
It should be added that most of the quantative 
data. (e.g. pulmonary vein diameter) can also be 
revealed by two-dimensional TEE. However, the 
opportunity of generating three-dimensional 
reconstructions of the left atrial anatomy gives the 
operator a more vivid impression of the individual 
LA morphology (comparable to MRI or MDCT 
reconstructions).  
 
Furthermore, 3D TEE might be an interesting 
technique for monitoring the movement of the 
catheters during an ablation procedure (see Fig. 
4). However, this is limited by the fact that deep 
sedation is required when the TEE probe remains 
in place for the entire procedure. Moreover, there 
might be an increased risk of esophageal injury 
(especially during RF ablation procedures).  
 
5. LIMITATIONS 
 
This is a feasibility study analysing our 
preliminary experience with catheter ablation of 
AF facilitated by the use of 3D TEE-
reconstructions. The aim of this study was to 
show the usefulness of 3D TEE for PV 
visualization prior to an ablation procedure. The 
study was not primarily designed to prove that 
this technique is equivalent to or superior to other 
imaging techniques (MDCT, MRI or intracardiac 
ultrasound). Therefore, no comparison to MDCT 
or MRI data is provided. Obviously, the results of 
this study have to be confirmed by a future study 
with a larger patient cohort and a direct 
comparison to MDCT or MRI scans. Morover, a 
detailed intra- and inter-examiner variability 
analysis concerning the echo examinations must 
be performed in a future study with a larger 
patient cohort. 
 
Furthermore, there are some technical limitations 
of 3D transesophageal echocardiography: first, 
the right pulmonary veins are sometines difficult 
to visualize. It should be pointed out that all 
pulmonary veins could be evaluated in only 84% 
of patients. In the remaining patients the operator 
has to rely on the invasive pulmonary vein 
angiography or use a different imaging technique 
(such as MRI, MDCT or intracardiac ultrasound).  
Second, the 3D TEE images can only be 
displayed in a manually-guided synchronized way 
during the ablation procedure on separate 
screens. No direct image fusion with the 
geometry created with a 3D mapping system 
(CARTO (Biosense Webster) or Navx/Ensite (St. 
Jude Medical, Saint Paul, MN, USA)) is available 
so far. Some technical modifications are needed 
to achieve this and the accuracy of these 3D 
reconstructions remains to be evaluated in future 
studies. 
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6. CONCLUSIONS 
 
Catheter ablation of atrial fibrillation can be 
performed safely and effectively based on prior 
3D TEE imaging. Three-dimensional TEE-
reconstructions provide an excellent overview 
over the individual left atrial and pulmonary vein 
morphology, thereby facilitating the procedure. 
Typical pitfalls (e.g. complex pulmonary vein 
morphology, varying distance between the LAA 
and the LSPV) can be revealed and the ablation 
strategy can be modified appropriately to avoid 
serious complications.   
 
Therefore, 3D TEE reconstructions might be of 
growing importance for catheter ablation of AF in 
the future. However, future randomized studies 
are needed to prove that this approach is superior 
to standard ablation procedures (e.g. using 3D 
MRI- / MDCT-reconstructions) with regard to 
success rates, complication rates and other 
parameters (e.g. radiation exposure).   
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